The story discusses the potential benefits in depth, which is good, but fails to quantify those benefits, which was a weak point.
Parents curious about these forthcoming treatments are likely already wondering if they’ll be affordable, but the story skirts any discussion of pricing.
The story rightly cautions that the technology is “experimental” and notes that additional research is needed. But if that’s the case, it’s not clear why this is newsworthy
Because it lacks information on costs, readers can’t answer an important question: Can I afford it?
Unfortunately the story relies more on patient anecdotes than evidence.
Financially-minded readers want to make a good investment not predicated on hype, and readers want to take a safe, effective drug.
This story’s focus on cautionary aspects of the drug’s use and marketing does a nice job of illuminating the complexity of drug introductions.
Despite an alarmist headline, this story on statin therapy is relatively thorough, with some notable exceptions.